Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.
IPO Year: 2021
Exchange: NASDAQ
Website: vaxxinity.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/8/2023 | $7.00 | Outperform | Robert W. Baird |
| 4/27/2022 | In-line | Evercore ISI | |
| 12/29/2021 | $18.00 | Buy | Jefferies |
| 12/7/2021 | $18.00 | Buy | Jefferies |
| 12/6/2021 | $21.00 | Buy | B of A Securities |
15-12G - Vaxxinity, Inc. (0001851657) (Filer)
DEF 14C - Vaxxinity, Inc. (0001851657) (Filer)
EFFECT - Vaxxinity, Inc. (0001851657) (Filer)
S-8 POS - Vaxxinity, Inc. (0001851657) (Filer)
S-8 POS - Vaxxinity, Inc. (0001851657) (Filer)
POS AM - Vaxxinity, Inc. (0001851657) (Filer)
10-K/A - Vaxxinity, Inc. (0001851657) (Filer)
PRE 14C - Vaxxinity, Inc. (0001851657) (Filer)
25 - Vaxxinity, Inc. (0001851657) (Filer)
8-K - Vaxxinity, Inc. (0001851657) (Filer)
U.S. stocks traded higher this morning, with the Dow Jones index surging over 400 points on Friday. Following the market opening Friday, the Dow traded up 1.17% to 38,673.45 while the NASDAQ rose 1.76% to 16,120.20. The S&P 500 also rose, gaining, 1.04% 5,116.83. Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Tech & Telecom Stocks Delivering High-Dividend Yields Leading and Lagging SectorsInformation technology shares rose by 2.5% on Friday. In trading on Friday, energy shares fell by 0.6%. Top Headline U.S. employers added 175,000 nonfarm payrolls in April, marking a reduction from the upwardly revised 315,000 reading in March and missing the expected 23
Gainers Helius Medical Tech (NASDAQ:HSDT) shares increased by 48.9% to $3.96 during Friday's pre-market session. The company's market cap stands at $3.5 million. Vaxxinity (NASDAQ:VAXX) shares moved upwards by 41.17% to $0.15. The company's market cap stands at $18.6 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 28.37% to $0.38. The market value of their outstanding shares is at $108.1 million. Healthcare Triangle (NASDAQ:HCTI) shares moved upwards by 19.56% to $1.47. The company's market cap stands at $6.8 million. Ardelyx (NASDAQ:ARDX) stock increased by 16.64% to $7.92. The company's market cap stands at $1.8 billion. As per the news, the Q1 earnings report came out ye
Shares of Apple Inc. (NASDAQ:AAPL) rose sharply in today's pre-market trading after the company reported better reported better-than-expected results for its second quarter. The company announced a $110-billion stock buyback program and a one-penny-per-share increase in its quarterly dividend. Apple shares jumped 5.9% to $183.24 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Vaxxinity, Inc. (NASDAQ:VAXX) gained 45.8% to $0.1519 in pre-market trading after falling 9% on Thursday. Vaxxinity recently announced its intention to voluntarily delist and deregister its Class A common stock. El Pollo Loco Holdings, Inc. (NASDAQ:LOCO) gained
Gainers Akili (NASDAQ:AKLI) stock moved upwards by 70.1% to $0.4 during Tuesday's regular session. The company's market cap stands at $31.4 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose 51.83% to $2.06. The company's market cap stands at $2.7 million. Eliem Therapeutics (NASDAQ:ELYM) shares rose 50.0% to $7.53. The company's market cap stands at $208.7 million. GeneDx Hldgs (NASDAQ:WGS) stock moved upwards by 45.99% to $16.06. The market value of their outstanding shares is at $418.4 million. The company's, Q1 earnings came out yesterday. Dare Bioscience (NASDAQ:DARE) stock moved upwards by 22.75% to $0.35. The company's market cap stands at $34.8 million. Lucid Diagnostic
Gainers GeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings came out today. InnovAge Holding (NASDAQ:INNV) shares increased by 7.25% to $3.99. The market value of their outstanding shares is at $542.2 million. Mustang Bio (NASDAQ:MBIO) shares increased by 5.48% to $0.25. The market value of their outstanding shares is at $2.5 million. Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 5.23% to $0.79. The market value of their outstanding shares is at $38.1 million. Seelos Therapeutics (NASDAQ:SEEL) shares increased by 4.88% to $0.29. The market
Shares of Teledyne Technologies Incorporated (NYSE:TDY) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and cut FY24 adjusted EPS guidance. Teledyne Technologies posted adjusted earnings of $4.55 per share, missing market estimates of $4.63 per share. The company's quarterly sales came in at $1.35 billion versus expectations of $1.40 billion, according to data from Benzinga Pro. Teledyne Technologies shares dipped 9.3% to $369.16 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) gained 136% to $0.3570. BranchOu
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 27.8% to $0.58 during Wednesday's regular session. The company's market cap stands at $4.4 million. Prenetics Global (NASDAQ:PRE) stock moved upwards by 26.25% to $5.77. The company's market cap stands at $70.4 million. Alterity Therapeutics (NASDAQ:ATHE) stock rose 15.02% to $2.45. The market value of their outstanding shares is at $21.3 million. Immutep (NASDAQ:IMMP) shares increased by 13.54% to $2.85. The market value of their outstanding shares is at $338.8 million. CareMax (NASDAQ:CMAX) shares rose 12.89% to $3.94. The market value of their outstanding shares is at $14.9 million. SINTX Techs (NASDAQ:SINT) stock moved
Vaxxinity Inc (NASDAQ:VAXX) shares are trading lower by 10% to $0.24 during Tuesday’s session. The stock is trading lower on continued volatility after the company announced its intention to voluntarily delist and deregister its Class A common stock. What Else? Vaxxinity has decided to delist from Nasdaq due to non-compliance with the minimum bid price requirement. This move aims to tackle low trading activity, which the company says has been an obstacle in raising capital and attracting investors. By delisting and deregistering, the company says it can concentrate its resources on research and development without being distracted by stock price fluctuations. The delisting is set t
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining more than 1% on Monday. The Dow traded up 1.02% to 38,373.22 while the NASDAQ rose 1.45% to 15,503.89. The S&P 500 also rose, gaining, 1.22% to 5,027.92. Check This Out: Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday Leading and Lagging SectorsFinancial shares climbed by 1.3% on Monday. In trading on Monday, materials shares rose by just 0.2%. Top Headline Shares of Zions Bancorporation, N.A. (NASDAQ:ZION) gained around 4% on Monday after the company reported upbeat earnings for its first quarter. The company posted a first-quarter FY24 revenue decline of 11.6% year-
Vaxxinity Inc (NASDAQ:VAXX) shares are trading lower by 47% to $0.25 during Monday’s session after the company announced its intention to voluntarily delist and deregister its Class A common stock. This decision follows non-compliance with Nasdaq’s minimum bid price requirement and aims to address low trading value and volume, which hinder the company’s ability to raise capital and attract investor interest. By delisting and deregistering, Vaxxinity intends to focus resources on research and development efforts without the distraction of stock price fluctuations. The delisting is expected to take effect around May 9, with potential trading on over-the-counter markets afterward. The com
Robert W. Baird initiated coverage of Vaxxinity with a rating of Outperform and set a new price target of $7.00
Evercore ISI initiated coverage of Vaxxinity with a rating of In-line
Jefferies resumed coverage of Vaxxinity with a rating of Buy and set a new price target of $18.00
Jefferies initiated coverage of Vaxxinity with a rating of Buy and set a new price target of $18.00
B of A Securities initiated coverage of Vaxxinity with a rating of Buy and set a new price target of $21.00
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G/A - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G - Vaxxinity, Inc. (0001851657) (Subject)
SC 13G - Vaxxinity, Inc. (0001851657) (Subject)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
3 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
4 - Vaxxinity, Inc. (0001851657) (Issuer)
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living. Data demonstrates target engagement and immunogenicity of the active immunotherapy UB-312 targeting pathological alpha-synuclein. CAPE CANAVERAL, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (OTC:VAXX), a U.S. company pioneering the development of a new class of medicines known as AIMs (active immunotherapy medicines), announced today that Nature Medicine has published groundbreaking exploratory data from the Company's Phase 1 clinical trial of UB-312 in patients with Parkinson's disease (PD). The succes
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu. To Shareholders of Vaxxinity, Inc.: Earlier today, we announced that we are delisting and deregistering our shares. A few weeks from now, we will no longer be publicly traded on the NASDAQ exchange. It is important to share why we made this decision to "go dark" and why we believe it is in the best interests of the company and our shareholders over
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. ("Vaxxinity", "we", "us" or the "Company") (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced its intention to voluntarily delist from the Nasdaq Global Market ("Nasdaq") and to deregister its Class A common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and suspend its reporting obligations under Section 15(d) of the Exchange Act. On February 9, 2024, the Company received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC indicating that the Company was no longer
CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado. Presentation details are as follows:Oral PresentationSession: ES2 - Emerging ScienceTitle: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson's DiseasePresenter: Jean-Cosme Dodart, Ph.D., CSO at VaxxinityDate & Time: April 16, 2024 at 5:54 pm MT The AAN Annual Meeting is the la
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. "2024 will prove to be a critical year for Vaxxinity as we refocus our efforts on our neurodegeneration programs and move closer to obtaining our company's first approval," said Mei Mei Hu, CEO of Vaxxinity. "Just this month, we presented exploratory biomarker data from our Phase 1 trial of UB-312 in Parkinson's patients: a first of its kind demonstrating target engagement of toxic alpha-sy
LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced positive clinical data from its UB-312 program in Parkinson's disease (PD) presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Disease, held virtually and in Lisbon, Portugal from March 5 to March 9, 2024. UB-312 is the first active immunotherapy candidate to show reduction of pathological alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of PD patients. UB-312 is designed to target aggregated forms of aSyn, the toxic
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results, which support the continued clinical development of VXX-401 as a candidat
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease and preclinical data from its anti-tau program in Alzheimer's disease at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal. Presentation details are as follows: Oral PresentationTitle: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson's DiseasePresenter: Jean-Cosme Dodart, Ph.D., SV
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida's (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate neurodegenerative diseases, having the potential to change the future of treatment by offering people an affordable and accessible therapeutic option. "O
CAPE CANAVERAL, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a collaboration with the University of Central Florida (UCF) to advance space medicine research. The research, funded by a grant from the State of Florida, aims to further the development of Vaxxinity's active immunotherapies to prevent and mitigate muscle and bone wasting, which are well known health challenges related to long-term spaceflight, and which share biological mechanisms implicated in highly prevalent age-related diseases. "If humanity is to become a spacefaring species, solving fundamental problems rela
Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity's leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023. He will remain as a member of Vaxxinity's board of directors. Peter will oversee the overall scientific direction of Vaxxinity's platform and programs, and lead the development efforts at Vaxxinity. "Get ready for the next wave of innovative drug science at V
Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories ("VaxxLabs") in Cape Canaveral, Fla., as corporate headquarters CAPE CANAVERAL, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, announced new appointments to the Board of Directors and the relocation of its corporate headquarters to Cape Canaveral, Fla. "Today's announcements reflect the strength of Vaxxinity's science and people and further equip us to achieve key research and commercial milestones as we prepare to launch our fir
DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today announced that Peter Powchik, M.D. is joining its Board of Directors and will be retiring as Vaxxinity's Executive Vice President, Research & Development. This transition will be effective March 31, 2022 and will increase the size of the Board to seven. "Peter is a rockstar of drug development who has contributed to the approval of over half a dozen new drugs that help patients to this day. We are fortunate to have him joining our Board where we may continue to leverage his considerable expertise to dev
DALLAS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the appointment of Jason Pesile, MBA, CPA, as Senior Vice President, Finance & Accounting. The Company also announced today the appointment of George Hornig, Chairman of Xometry, to its Board of Directors. Mr. Hornig will be the new independent director to chair the Audit Committee, with current Board members Greg Blatt and Peter Diamandis moving to chair the Compensation Committee and Nominating and Governance Committee, respectively. "We are thrilled to welcome Jason to our management team and George to the Vaxx